{
  "id": 12628429,
  "title": "FibroBiologics files patent for cell-based peptide delivery",
  "url": "https://urgent.news/2026/10/07/fibrobiologics-files-patent-for-cell-based-peptide-delivery",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T12:44:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/fibrobiologics-files-patent-for-cellbased-peptide-delivery-93CH-4936686"
  },
  "original_language": "en",
  "account": "Houston-based FibroBiologics, Inc. has filed a U.S. patent application for a groundbreaking cell-based technology aimed at producing peptides, including GLP-1, GIP, and GLP-2, within the human body. This innovation contrasts with existing GLP-1-based medicines, which typically demand frequent injections or daily pills for weight loss and diabetes management.\n\nThe patent application proposes engineering cells to produce and discharge therapeutic peptides consistently following a single administration. These cells would be organized into three-dimensional structures known as spheroids or organoids, providing a continuous production site for peptides within the body. The patent covers applications spanning gastrointestinal diseases, autoimmune and inflammatory disorders, wound healing, tissue regeneration, hormone deficiencies, cancer, and age-related conditions.\n\nPete O’Heeron, FibroBiologics' Founder and CEO, highlighted the technology's potential to simultaneously manufacture multiple therapeutic proteins and peptides in varying quantities. Immune-evasive modifications, safety switches, and encapsulation in biocompatible scaffolds or retrievable devices are also included in the patent application. FibroBiologics, a clinical-stage biotechnology firm, holds over 270 U.S. and international patents and patent applications across various clinical domains. However, the patent application does not signify an approved or commercially available product.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}